Abscesses due to Mycobacterium abscessus linked to injection of unapproved alternative medication

Emerging Infectious Diseases

Volumn 5, Issue 5, 1999, Pages 681-687

  Galil, Karin ^a   Miller, Lisa A ^b   Yakrus, Mitchell A ^a   Wallace Jr , Richard J ^c   Mosley, David G ^d   England, Bob ^d   Huitt, Gwen ^e   McNeil, Michael M ^a   Perkins, Bradley A ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b Colorado Dept Pub Hlth Environ ^*  (United States)

^c UNIVERSITY OF TEXAS HEALTH CENTER   (United States)

^d ARIZONA DEPARTMENT OF HEALTH SERVICES   (United States)

^e NATIONAL JEWISH MEDICAL AND RESEARCH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HYDROCORTISONE; THIOMERSAL; TISSUE EXTRACT;

ABSCESS; ADOLESCENT; ADRENAL CORTEX; ADRENAL INSUFFICIENCY; ADULT; AGED; ALTERNATIVE MEDICINE; ARTICLE; BACTERIUM CULTURE; CONTROLLED STUDY; DRUG CONTAMINATION; EPIDEMIC; FATIGUE; FEMALE; FOOD AND DRUG ADMINISTRATION; HUMAN; INJECTION SITE; INTRAMUSCULAR DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; MYCOBACTERIOSIS; MYCOBACTERIUM ABSCESSUS; QUESTIONNAIRE; UNITED STATES; WEIGHT REDUCTION;

EID: 0032718842     PISSN: 10806040     EISSN: None     Source Type: Journal    
DOI: 10.3201/eid0505.990509     Document Type: Article

References (31)

1. Eisenberg DM, Davis RB, Ettner SL, Appel S, Wilkey S, Van Rompay M, et al. Trends in alternative medicine use in the United States. JAMA 1988;280:1569-75.
2. Osier W. On six cases of Addison's disease with the report of a case greatly benefited by the use of suprarenal extract. International Medical Magazine 1895;4:3-11.
3. Eggleston C, Weiss S. Adrenal cortical hormone therapy. Am J Med Sci 1939;197:718-29.
4. Hypoglycemia Association. 1998. Bulletin #96. Available from: URL: http://fred.net/slowup/hai96.html.
5. Infection with Mycobacterium abscessus associated with intramuscular injection of adrenal cortex extract - Colorado and Wyoming, 1995-1996. MMWR Morb Mortal Wkly Rep 1996;45:713-5.
6. Smithwick RW, Bigbie MR Jr, Ferguson RB, Karlix MA, Wallis CK. Phenolic acridine orange fluorescent stain for mycobacteria. J Clin Microbiol 1995;33:2763-4.
7. Butler WE, Jost KC Jr, Kilburn JO. Identification of mycobacteria by high-performance liquid chromatography. J Clin Microbiol 1991;29:2468-72.
8. Yakrus MA, Reeves MW, Hunter SB. Characterization of isolates of Mycobacterium avium serotypes 4 and 8 from patients with AIDS by multilocus enzyme electrophoresis. J Clin Microbiol 1992;30:1474-8.
9. Wallace RJ Jr, Zhang Y, Brown BA, Fraser V, Mazurek GH, Maloney S. DNA large restriction fragment patterns of sporadic and epidemic nosocomial strains of Mycobacterium chelonae and Mycobacterium abscessus. J Clin Microbiol 1993;31:2697-701.
10. Tenover FC, Arbeit RD, Goering RV, Mickelsen PA, Murray BE, Persing DH, Swaminathan B. Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing. J Clin Microbiol 1995;33:2233-9.
11. Swenson JM, Wallace RJ Jr, Silcox VA, Thornsberry C. Antimicrobial susceptibility of five subgroups of Mycobacterium fortuitum and Mycobacterium chelonae [published erratum appears in Antimicrob Agents Chemother 1986 Apr;29:720]. Antimicrob Agents Chemother 1985;28:807-11.
12. Steingrube VA, Wallace RJ Jr, Steele LC, Pang YJ. Mercuric reductase activity and evidence of broad-spectrum mercury resistance among clinical isolates of rapidly growing mycobacteria. Antimicrob Agents Chemother 1991;35:819-23.
13. U.S. District Court, Southern District of Florida. Complaint for preliminary and permanent injunction. Miami (FL): The Court; 1997. CIV-Case 97-1083.
14. Brown BA, Wallace RJ Jr, Onyi GO, De Rosas V, Wallace RJ III. Activities of four macrolides, including clarithromycin, against Mycobacterium fortuitum, Mycobacterium chelonae, and M. chelonae-like organisms. Antimicrob Agents Chemother 1992;36:180-4.
15. Kuritsky JN, Bullen MG, Broome CV, Silcox VA, Good RC, Wallace RJ Jr. Sternal wound infections and endocarditis due to organisms of the Mycobacterium fortuitum complex. Ann Intern Med 1983;98:938-9.
16. Safranek TJ, Jarvis WR, Carson LA, Cusick LB, Bland LA, Swenson JM, et al. Mycobacterium chelonae wound infections after plastic surgery employing contaminated gentian violet skin-marking solution. N Engl J Med 1987;317:197-201.
17. Wenger JD, Spika JS, Smithwick RW, Pryor V, Dodson DW, Carden GA, et al. Outbreak of Mycobacterium chelonae infection associated with use of jet injectors. JAMA 1990;264:373-6.
18. Lowry PW, Jarvis WR, Oberle AD, Bland LA, Silberman R, Bocchini JA Jr, et al. Mycobacterium chelonae causing otitis media in an ear-nose-and-throat practice. N Engl J Med 1988;319:978-82.
19. Bolan G, Reingold AL, Carson LA, Silcox VA, Woodley CL, Hayes PS, et al. Infections with Mycobacterium chelonei in patients receiving dialysis and using processed hemodialyzers. J Infect Dis 1985;152:1013-9.
20. Lowry PW, Beck-Sague CM, Bland LA, Aguero SM, Arduino MJ, Minuth AN, et al. Mycobacterium chelonae infection among patients receiving high-flux dialysis in a hemodialysis clinic in California. J Infect Dis 1990;161:85-90.
21. Inman PM, Beck A, Brown AE, Stanford JL. Outbreak of injection abscesses due to Mycobacterium abscessus. Arch Dermatol 1969;100:141-7.
22. Borghans JG, Stanford JL. Mycobacterium chelonei in abscesses after injection of diphtheria-pertussistetanus-polio vaccine. American Review of Respiratory Disease 1973;107:1-8.
23. Gremillion DH, Mursch SB, Lerner CJ. Injection site abscesses caused by Mycobacterium chelonei. Infection Control 1983;4:25-8.
24. Camargo D, Saad C, Ruiz F, Ramirez ME, Lineros M, Rodriguez G, et al. Iatrogenic outbreak of M. chelonae skin abscesses. Epidemiol Infect 1996;117:113-9.
25. Villanueva A, Calderon RV, Vargas BA, Zhang Y, Sander P, Onyi GO, et al. Report on an outbreak of postinjection abscesses due to Mycobacterium abscessus, including management with surgery and clarithromycin therapy and comparison of strains by random amplified polymorphic DNA polymerase chain reaction. Clin Infect Dis 1997;24:1147-53.
26. Tebas P, Sultan F, Wallace RJ Jr, Fraser V. Rapid development of resistance to clarithromycin following monotherapy for disseminated Mycobacterium chelonae infection in a heart transplant patient. Clin Infect Dis 1995;20:443-4.
27. Driscoll MS, Tyring SK. Development of resistance to clarithromycin after treatment of cutaneous Mycobacterium chelonae infection. Journal of the American Academy of Dermatology 1997;36:495-6.
28. Wallace RJ Jr, Tanner D, Brennan PJ, Brown BA. Clinical trial of clarithromycin for cutaneous (disseminated) infection due to Mycobacterium chelonae. Ann Intern Med 1993;119:482-6.
29. Wallace RJ Jr, Meier A, Brown BA, Zhang Y, Sander P, Onyi GO, et al. Genetic basis for clarithromycin resistance among isolates of Mycobacterium chelonae and Mycobacterium abscessus. Antimicrob Agents Chemother 1996;40:1676-81.
30. Alternative medicine: a report to the National Institutes of Health on alternative medical systems and practices in the United States, Workshop on Alternative Medicine; 1992 Sep 14-16; Chantilly, Virginia. Washington: U.S. Government Printing Office; 1993.
31. Villaire M. Centers provide OAM with 'deliverables'. Altern Ther Health Med 1997;3:20-4.